Freyr Solutions

Join

Sign In

Sign Up

Night Mode

Freyr Solutions

Search

Philippines Pharmaceutical Market Entry 2026

Malaysia Pharmaceutical Regulations 2026: Key NPRA Updates and Market Entry Considerations Manufacturers planning pharmaceutical market entry into Malaysia in 2026 must prepare for a series of important regulatory reforms introduced by the National Pharmaceutical Regulatory Agency (NPRA). Effective from 2025 onward, these updates will significantly impact product registration, pharmacovigilance...

Freyr Solutions

2026-05-13 09:49:03

Philippines Pharmaceutical Market Entry 2026

Major Regulatory Updates Shaping Market Entry in 2026 1. Revised Product Registration Framework Administrative Order (AO) No. 2024-0013, effective in 2025, significantly updates the registration process for pharmaceutical products and active pharmaceutical ingredients (APIs) intended for human use. The revised framework: Aligns submissions with ASEAN Common Technical Dossier (ACTD) and CTD...

Freyr Solutions

2026-05-13 09:47:14

ARTG Inclusion in Australia

Navigating ARTG Inclusion: Building a Smarter Regulatory Strategy for Australia Freyr supports pharmaceutical companies in navigating Australia’s highly regulated and commercially significant healthcare market. As regulatory expectations continue to evolve, gaining inclusion in the Australian Register of Therapeutic Goods (ARTG) has become more than a procedural requirement—it is...

Freyr Solutions

2026-05-13 04:15:45

Japan’s Drug Lag & Drug Loss

Japan’s Drug Lag and Drug Loss: Turning Regulatory Complexity into Strategic Opportunity Freyr helps pharmaceutical companies navigate one of the world’s most sophisticated healthcare markets—Japan. While Japan remains a highly attractive destination for innovative therapies, two major challenges continue to influence market access and regulatory planning: drug lag and drug...

Freyr Solutions

2026-05-13 04:13:38

Generic & Value-Added Medicines Opportunity in Africa

Africa’s Pharmaceutical Market: Emerging Opportunities for Generics and Value-Added Medicines Africa’s pharmaceutical sector is entering a new phase of growth, creating significant opportunities for generic drug manufacturers and developers of value-added medicines (VAMs). Rising healthcare demand, evolving regulatory systems, and increasing investment in local manufacturing are...

Freyr Solutions

2026-05-07 12:45:06

China’s Patent Linkage System & Impact on Drug Registration

China’s pharmaceutical regulatory landscape has undergone significant reform with the introduction of the patent linkage system, a critical mechanism shaping drug registration in China and market entry strategies for both innovators and generic manufacturers. Implemented under the amended Patent Law and associated measures, the system links patent status with marketing authorization...

Freyr Solutions

2026-05-06 04:16:27

FDA 2026 NAMs Guidance on Human-Relevant Evidence

The FDA’s March 2026 draft guidance on new approach methodologies (NAMs) is more than a policy statement; it is a signal that evidence from non-animal testing is moving closer to mainstream Regulatory decision-making. While the draft does not impose a blanket acceptance rule for sponsors, it clearly articulates a scientific framework that explains when and how NAMs can inform drug...

Freyr Solutions

2026-05-06 04:11:46

Packaging Artwork Operations with Freyr’s Global Studio

Packaging artwork is no longer just a design activity — it is a critical operational function that connects regulatory compliance, supply chain readiness, and brand consistency across markets. At Freyr, our Packaging Artwork Studio is built specifically to support the complex needs of pharma, healthcare, and consumer product companies through a fully integrated creative, adaptation, and...

Freyr Solutions

2026-05-06 04:10:00

The Strategic Role of Artwork Process Consulting in Pharma

In today’s regulated industries, packaging artwork and labeling processes sit at the intersection of regulatory compliance, product supply, and brand integrity. Yet in many organizations, artwork operations have evolved organically over time—leading to fragmented workflows, manual dependencies, inconsistent governance, and limited visibility into performance. This is where Artwork...

Freyr Solutions

2026-05-06 04:06:33

Rethinking Pharma Quality Systems for 2026

Recent industry data highlights a clear shift in how pharmaceutical quality systems are being evaluated, and why they must evolve: Over 93% of global pharma sites achieve acceptable inspection outcomes, indicating widespread baseline compliance In India, Official Action Indicated (OAI) rates have declined significantly over the past decade, reflecting stronger quality maturity amid stricter...

Freyr Solutions

2026-05-06 04:04:27

Continuous Vendor Compliance in GxP Environments

In 2026, pharmaceutical companies are facing increasing Regulatory scrutiny not just for their internal operations, but for the performance of their entire supplier ecosystem. The following industry insights highlight the urgency of strengthening vendor compliance strategies: A significant proportion of Regulatory observations are now linked to third-party and supplier-related gaps,...

Freyr Solutions

2026-05-06 04:00:44

2026 China Regulations Readiness Checklist

LinkedInXFacebookWhatsAppTeamsShare China’s pharmaceutical market is one of the fastest-growing globally, and 2026 is shaping up to be a pivotal year for Regulatory compliance and market entry. With evolving policies from the National Medical Products Administration (NMPA), global pharma companies need to be fully prepared to meet China’s requirements for drug registration,...

Freyr Solutions

2026-05-04 05:32:13

See More